IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
37.02
+0.78 (2.15%)
Aug 7, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, IDEAYA Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $52.15. The average 1-year stock price forecast is 40.87% higher than the current stock price, while the lowest is $31 (-16.26%) and the highest is $65 (+75.58%).
Price Target: $52.15 (+40.87%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 13 | 11 | 11 | 11 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $58 | Buy | Maintains | $58 | +56.67% | Aug 8, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Reiterates $50 | Buy | Reiterates | $50 | +35.06% | Aug 7, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $45 → $42 | Buy | Maintains | $45 → $42 | +13.45% | Aug 6, 2026 |
| Wedbush | Wedbush | Buy Maintains $58 → $60 | Buy | Maintains | $58 → $60 | +62.07% | Aug 5, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $63 → $59 | Buy | Reiterates | $63 → $59 | +59.37% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
39.83M
from 218.71M
Decreased by -81.79%
Revenue Next Year
115.49M
from 39.83M
Increased by 189.97%
EPS This Year
-4.64
from -1.28
EPS Next Year
-4.08
from -4.64
EPS and Forward PE are based on non-GAAP adjusted numbers.